Abstract
The COVID-19 pandemic caused by SARS-CoV-2 has led to the large-scale expression of scientific and technological acquisitions, so that it has been possible to have more safe and effective vaccines available in less than a year. Vaccines based on mRNA and those based on nonreplicative viral vector are the most widely used vaccines at this time. They have demonstrated the ability to meet a wide-ranging goal of producing a pandemic vaccine and a large number of vaccines in various stages of preclinical or clinical studies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
